We are live on ! Find out more
FIS

FCPM III Services Portfolio holdings

AUM $722M
1-Year Est. Return 73.61%
This Fund
S&P 500
This Quarter Est. Return
+0.37%
1 Year Est. Return
+73.61%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$722M
AUM Growth
-$40.7M
Cap. Flow
-$6.41M
Cap. Flow %
-0.89%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics
DMRA
+$62.7M
2
VOR icon
Vor Biopharma
VOR
+$7.05M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$62.1M
2
DYN icon
Dyne Therapeutics
DYN
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.7B
$294M 40.77%
9,198,900
– –
DYN icon
2
Dyne Therapeutics
DYN
$3.92B
$84.2M 11.66%
4,644,386
-818,460
-15% -$14.1M
VOR icon
3
Vor Biopharma
VOR
$980M
$73.5M 10.17%
4,117,354
+500,000
+14% +$7.05M
ENGN icon
4
enGene Therapeutics
ENGN
$122M
$65.6M 9.08%
9,632,561
– –
MPLT
5
MapLight Therapeutics
MPLT
$1.72B
$65.6M 9.08%
3,226,400
– –
DMRA
6
Damora Therapeutics
DMRA
$1.94B
$63.2M 8.75%
+2,441,000
New +$62.7M
CBIO
7
Crescent Biopharma
CBIO
$407M
$30.8M 4.27%
1,677,852
– –
REPL icon
8
Replimune Group
REPL
$859M
$21.5M 2.97%
2,808,368
– –
BCYC
9
Bicycle Therapeutics
BCYC
$294M
$16.1M 2.23%
3,468,430
– –
ENGNW icon
10
enGene Therapeutics Warrants
ENGNW
$3.35M
$7.28M 1.01%
2,878,148
– –
RAPT
11
DELISTED
RAPT Therapeutics
RAPT
– –
-1,833,333
Closed -$62.1M

Similar funds

ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
ZAM
Zevin Asset Management Boston, Massachusetts $723M AUM 15.62% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $723M AUM 24.23% 1-Year Est. Return
UW
Unique Wealth Clearwater, Florida $723M AUM 16.35% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
FFM
FengHe Fund Management Singapore $724M AUM 196.18% 1-Year Est. Return
WLIM
White Lighthouse Investment Management Bedford, Massachusetts $721M AUM 16.12% 1-Year Est. Return

FCPM III Services's Q1 2026 Portfolio in Review

As of Q1 2026, FCPM III Services held 11 positions worth $722M, down 5.3% from $763M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

FCPM III Services's Q1 2026 filing shows 1 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was Damora Therapeutics: 2,441,000 shares worth $63.2M. The largest sale was RAPT Therapeutics, an estimated $62.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

  • FCPM III Services's largest Q1 2026 buy was Damora Therapeutics: 2,441,000 shares worth $63.2M.
  • FCPM III Services added most to Vor Biopharma in Q1 2026, an estimated $7.05M increase.
  • FCPM III Services's biggest Q1 2026 reduction was Dyne Therapeutics, cutting an estimated $14.1M.
  • FCPM III Services fully exited RAPT Therapeutics in Q1 2026, selling an estimated $62.1M.
  • FCPM III Services's ten largest holdings make up 100% of its $722M portfolio in Q1 2026.
  • FCPM III Services opened 1 new position and closed 1 in Q1 2026.
  • FCPM III Services's portfolio value fell 5.3% quarter-over-quarter to $722M.

Based on FCPM III Services's 13F filing for Q1 2026, filed 15 May 2026.